Seeking Alpha

PLX
Protalix BioTherapeutics, Inc

5/26/2012, 5:48 PM ET
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
PLX Market Currents more »
  • May 2 Canaccord takes some of the shine off Protalix's (PLX +13%) early morning 27% run-up in the wake of the FDA's approval of its new treatment for Gaucher disease, downgrading the shares to Hold after digging deeper into the report. The firm says it sees only modest U.S. but solid Israel/ROW potential, and EU approval may in fact be blocked.
    Comment!
    [Healthcare, On the Move]
PLX in Focus more »
PLX Latest Transcript more »
Currently, there are no transcripts for PLX.
PLX Cramer more »
Currently, there are no Cramer articles on PLX.
PLX Instablog posts more »
  • Equity To Commodity Disconnect?
    Wed, May 2 • Garfield23 • 1 Comment
  • Darker Shade of Cloudy
    Mon, Oct 10, 2011 • Ilene at PSW • Comment!
  • Protalix Biotherapeutics – Using Plants to Treat Human Disease
    Mon, Sep 12, 2011 • Ilene at PSW • Comment!
  • PROTALIX Submits Reply to FDA CRL as my evalutaion
    Tue, Aug 2, 2011 • Joe Gantoss • 3 Comments
  • Protalix Major Shareholder Biocell To Maintain Holding.
    Mon, Jul 18, 2011 • Joe Gantoss • Comment!
Write a post on PLX
PLX StockTalks
PLX vs. ETF Alternatives
Company Description

We are a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on our proprietary ProCellExTM protein expression system, or ProCellEx. Using our ProCellEx system, we are developing a pipeline of proprietary and biosimilar or... More

Sector: Healthcare
Industry: Biotechnology
Country: United States